Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydrocortisone for Prevention of Atrial Fibrillation After Mitral Valve Surgery
NCT03682393Phase 3Withdrawn
- Sponsor
- Kuopio University Hospital
- Start
- Jan 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydrocortisone in Atrial fibrillation (AFib), sponsored by Kuopio University Hospital. Planned start Jan 2020; status: withdrawn.
02
Drugs
hydrocortisone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03682393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03682393.